規制申請のためにeCTDベンダーを選定するのはいつが適切ですか？
As your company moves towards the regulatory submission of a marketing application to a health…
Certara2022年1月10日
Certara University Express Webinar: Part 2: Introduction to RsNLME and overview of expanded workflow
Introduction to RsNLME and its capabilities for population PK/PD modeling.
Certara2022年1月5日
Certara University Express Webinar: Part 1: Introduction to RsNLME (R speaks NLME)
Introduction to RsNLME and its capabilities for population PK/PD modeling.
Certara2022年1月5日
Certara Acquires Integrated Nonclinical Development Solutions
Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc.,…
Certara2022年1月5日
Strategic Application of PBPK Modeling for Predicting DDIs & the Effects of Smoking & Organ Impairment
Olanzapine is a highly effective antipsychotic, but its uses are limited by the risk of…
Certara2021年12月23日
ScienceDirect: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Observational studies have postulated a therapeutic role of metformin in treating COVID-19. We conducted ...(cont.)
Certara2021年12月22日
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 SimcypTM and PhoenixTM software licenses across 12 divisions and offices…
Certara2021年12月21日
P21 Releases New PMDA Validation Engine
New PMDA Engine Pinnacle 21 is happy to announce the latest Validation Engine for submissions…
Certara2021年12月20日
Exploring Changes in SDTMIG 3.4 & ADaMIG 1.3
On November 29th 2021, CDISC released updated versions of SDTM and ADaM, including standardized structures…
Certara2021年12月16日
